Economic Dynamics: Cost-Savings vs. Control
In 2026, the FSP model is proven to be approximately 30–40% more cost-effective than full-service outsourcing for large-scale, long-term programs in South Korea.
Scalability: South Korean biotechs use FSPs to "flex" their workforce. If a trial is delayed, they can scale down their FSP headcount in 30 days, avoiding the heavy severance costs associated with permanent Korean labor laws.
Sovereignty over Data: A key cultural trend in 2026 is the "Sponsor's Choice" for technology. In an FSP model, the sponsor retains their own Electronic Data Capture (EDC) system, and the FSP provides the experts to run it, preventing "vendor lock-in."
Global Alignment: For Korean companies expanding to the US or EU, global FSPs (like Parexel or Syneos) provide local Korean staff who follow global Standard Operating Procedures (SOPs), ensuring the data is "submission-ready" for the FDA and EMA.